Tirzepatide works by activating two gut hormone receptors at the same time, the glucose dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide 1 (GLP-1) receptor. Both belong to the incretin system, the signaling network that the intestine uses to tell the pancreas, the brain, and fat tissue that a meal has arrived. Earlier medications in this class, including semaglutide and liraglutide, act on the GLP-1 receptor alone. Tirzepatide was engineered to activate both, and in every head to head trial published so far the dual approach has produced larger reductions in weight and blood glucose than a GLP-1 receptor agonist used on its own.
This article explains the pharmacology in plain language and is educational rather than individualized, since tirzepatide is a prescription medication and decisions about whether it is appropriate belong in a conversation with a licensed clinician.
Key Takeaways
- Tirzepatide is a 39 amino acid synthetic peptide built on the native GIP sequence and modified with a C20 fatty diacid chain that binds albumin, which extends its half life to about 5 days and allows once weekly injection.
- The molecule binds the GIP receptor with affinity similar to native GIP and the GLP-1 receptor with roughly five fold lower affinity than native GLP-1, so it is often described as GIP weighted rather than balanced.
- Through the GLP-1 receptor, tirzepatide increases insulin release only when glucose is elevated, suppresses glucagon, slows gastric emptying, and reduces appetite through receptors in the hypothalamus and hindbrain.
- Through the GIP receptor, tirzepatide adds a second insulin signal, improves how fat tissue stores and buffers lipids, appears to enhance insulin sensitivity, and in animal models reduces the nausea that GLP-1 receptor activation can cause.
- In SURPASS-2, tirzepatide 15 mg lowered HbA1c by 2.30 percentage points and body weight by 11.2 kg over 40 weeks, compared with 1.86 points and 5.7 kg for semaglutide 1 mg. In SURMOUNT-5, tirzepatide produced 20.2 percent weight loss at 72 weeks versus 13.7 percent for semaglutide 2.4 mg.
- The GIP half of the mechanism is still debated, because a GIP receptor antagonist combined with a GLP-1 agonist has also produced weight loss in trials, and researchers have not settled why activation and blockade both appear to help.
What is tirzepatide, chemically?
Tirzepatide is a single synthetic peptide of 39 amino acids whose backbone is based on the sequence of native GIP, with selected substitutions borrowed from GLP-1 so that the molecule can activate both receptors. Two of the amino acids are non natural (alpha aminoisobutyric acid) and were placed to protect the peptide from the enzyme dipeptidyl peptidase 4, which normally destroys native incretin hormones within minutes.
The most consequential modification is a 20 carbon fatty diacid attached through a linker at position 20. This chain binds reversibly to albumin in the blood, which shields the peptide from breakdown and renal clearance, and the result is an elimination half life of approximately 5 days, long enough that a single weekly injection maintains continuous receptor activation. Tirzepatide is metabolized by proteolytic cleavage of the peptide backbone, beta oxidation of the fatty chain, and amide hydrolysis, and it does not rely on the cytochrome P450 enzymes that drive most drug interactions.
Figure 1
One Molecule, Two Receptors: Where Tirzepatide Acts and What Each Receptor Contributes
Sources: Willard et al., JCI Insight 2020; Coskun et al., Molecular Metabolism 2018; Mounjaro and Zepbound prescribing information.
What does the GLP-1 receptor do when tirzepatide activates it?
The GLP-1 receptor accounts for the effects most people associate with this drug class: glucose dependent insulin release, glucagon suppression, slower gastric emptying, and reduced appetite. Native GLP-1 is released from L-cells in the distal intestine after a meal, and GLP-1 receptors are found on pancreatic beta cells, on the vagal nerves that serve the stomach, and in several brain regions including the arcuate nucleus of the hypothalamus and the area postrema of the hindbrain.
Pancreas. GLP-1 receptor activation raises cyclic AMP inside beta cells, which amplifies insulin secretion, but only when blood glucose is elevated. This glucose dependence is the reason tirzepatide alone rarely causes hypoglycemia. The same signal restrains alpha cells from releasing glucagon after meals, which reduces the liver's glucose output.
Stomach. GLP-1 receptor activation slows the rate at which food leaves the stomach. The effect is strongest in the first weeks of treatment and after each dose increase, and it attenuates with continued exposure, a pattern called tachyphylaxis, which explains why nausea and fullness tend to peak after titration steps and then ease. Slower emptying also flattens the post meal glucose rise.
Brain. GLP-1 receptors in the hypothalamus and hindbrain reduce hunger and increase satiety, and neuroimaging studies of GLP-1 receptor agonists show reduced activation in reward regions in response to food cues, which many patients describe as a quieting of food noise. In an 18 week study using a metabolic chamber, tirzepatide reduced ad libitum energy intake by roughly 500 calories per day, which is where most of the weight loss comes from.
What does the GIP receptor add?
The GIP receptor contributes a second insulin signal, a direct effect on fat tissue, and an additional appetite signal in the brain that appears to complement GLP-1 rather than duplicate it. Native GIP is released from K-cells in the upper small intestine, and its receptors are found on beta cells, on adipocytes, in bone, and in the hypothalamus and hindbrain.
Pancreas. GIP is the more powerful of the two native incretins in healthy people, accounting for a larger share of the post meal insulin response. In type 2 diabetes the beta cell becomes relatively resistant to GIP, and one of the notable findings from tirzepatide research is that GLP-1 receptor activation appears to restore GIP responsiveness, so the two signals reinforce each other.
Fat tissue. Adipocytes express GIP receptors but not GLP-1 receptors. GIP receptor activation increases blood flow to fat tissue after meals, promotes healthy storage of dietary fat, and improves the tissue's ability to buffer lipids rather than spilling them into the liver and muscle. Better lipid buffering is one proposed explanation for why tirzepatide improves insulin sensitivity beyond what weight loss alone predicts.
Brain. GIP receptors in the hypothalamus reduce food intake in animal studies, and GIP receptor activation in the hindbrain has been shown in rodent and primate models to reduce the nausea and vomiting triggered by GLP-1 receptor agonists. This may be part of why tirzepatide reaches higher levels of effective receptor activation with a gastrointestinal side effect profile broadly similar to semaglutide.
| Tissue | GLP-1 receptor | GIP receptor |
|---|---|---|
| Pancreatic beta cell | Glucose dependent insulin release | Second insulin signal; sensitivity restored by GLP-1 |
| Pancreatic alpha cell | Suppresses glucagon | Little direct effect at high glucose |
| Stomach | Slows emptying; attenuates over time | No meaningful direct effect |
| Adipose tissue | No receptors on adipocytes | Lipid buffering, blood flow, adiponectin |
| Hypothalamus and hindbrain | Satiety, lower reward response | Lower intake; less nausea in animal models |
Summary of published receptor pharmacology. Human data on the direct GIP contribution are limited, and the animal findings on nausea have not been fully replicated in people.
Why does activating both receptors work better than GLP-1 alone?
Dual agonism produces larger effects because the two receptors act on partly different tissues and partly different pathways, so their contributions add rather than overlap. Two head to head trials make this concrete.
SURPASS-2 randomized 1,879 adults with type 2 diabetes to tirzepatide 5, 10, or 15 mg or to semaglutide 1 mg for 40 weeks. HbA1c fell by 2.01, 2.24, and 2.30 percentage points with the three tirzepatide doses, compared with 1.86 points for semaglutide, and body weight fell by 7.6, 9.3, and 11.2 kg, compared with 5.7 kg. Every tirzepatide dose was superior to semaglutide on both outcomes.
Figure 2
SURPASS-2 at 40 Weeks: HbA1c and Body Weight Reduction With Tirzepatide Versus Semaglutide 1 mg in Type 2 Diabetes
Sources: Frías et al., SURPASS-2, New England Journal of Medicine 2021 (1,879 participants, 40 weeks). Individual results vary.
SURMOUNT-5 randomized 751 adults with obesity but without diabetes to the maximum tolerated dose of tirzepatide or semaglutide 2.4 mg for 72 weeks. Mean weight loss was 20.2 percent with tirzepatide and 13.7 percent with semaglutide, a difference of about 6.5 percentage points, and nearly a third of tirzepatide participants lost 25 percent or more of their body weight compared with about 16 percent of semaglutide participants.
A mechanistic clamp study published in the Lancet Diabetes and Endocrinology in 2022 adds a further clue. Over 28 weeks in people with type 2 diabetes, tirzepatide 15 mg improved whole body insulin sensitivity, measured by hyperinsulinemic euglycemic clamp, substantially more than semaglutide 1 mg, and the difference persisted after statistical adjustment for the difference in weight loss. Tirzepatide also raised adiponectin, a hormone secreted by healthy fat tissue, which is consistent with a direct GIP effect on adipocytes.
Figure 3
How Weight Loss Was Distributed Among Participants on Tirzepatide 15 mg in SURMOUNT-1 at 72 Weeks
Sources: Jastreboff et al., SURMOUNT-1, New England Journal of Medicine 2022. Categories calculated from reported proportions reaching each weight loss threshold. Individual results vary.
How does the once weekly dosing work?
A weekly injection works because the albumin bound peptide is cleared so slowly that concentrations never fall to zero between doses. After a subcutaneous injection, tirzepatide reaches peak concentration between 8 and 72 hours, and with a half life of about 5 days each dose is still roughly 40 percent present when the next one is given, so concentrations accumulate over the first several weeks and reach a steady state after approximately four weekly doses.
This accumulation is the reason the prescribing information holds each dose for at least four weeks before escalating. Starting at 2.5 mg and increasing in 2.5 mg steps allows the gut and the brain to adapt to each concentration plateau, which reduces gastrointestinal side effects. The steady state also means that a single missed dose does not remove the drug from the body, and it is why the medication takes months rather than days to reach its full effect on weight.
Figure 4
Why Weekly Dosing Reaches a Plateau: Modeled Accumulation of Tirzepatide Over Five Weekly Doses With a 5 Day Half Life
Sources: Modeled from the approximately 5 day elimination half life and 8 to 72 hour time to peak reported in the Mounjaro and Zepbound prescribing information. Illustrative, not patient data.
How quickly do the different effects appear?
Appetite suppression begins within the first one to two weeks, gastric effects peak during titration, glucose improvements are measurable within 4 to 12 weeks, and weight loss continues for well over a year. In SURMOUNT-1, weight loss with tirzepatide 15 mg was approximately 6 to 7 percent at week 12, about 16 percent at week 36, and 20.9 percent at week 72, with the curve still shallowly descending at the study's end. Blood pressure, triglycerides, and liver fat typically improve in parallel with weight, while HbA1c changes tend to appear earlier because they reflect the direct pancreatic effects.
Figure 5
Time Course of Weight Change Over 72 Weeks in SURMOUNT-1: Tirzepatide 15 mg Versus Placebo
Sources: Jastreboff et al., SURMOUNT-1, New England Journal of Medicine 2022 (2,539 participants, 72 weeks). Individual results vary.
What remains unexplained about GIP?
The precise role of GIP is the most debated question in incretin pharmacology, because both activating and blocking the GIP receptor appear to produce weight loss when combined with GLP-1 agonism. A GIP receptor antagonist paired with a GLP-1 receptor agonist has produced substantial weight loss in early trials, and a leading hypothesis is that chronic GIP receptor agonism desensitizes the receptor so thoroughly that it becomes functionally similar to blockade. The field agrees only that GIP signaling matters, and that tirzepatide's clinical results stand regardless of which explanation wins.
A second open question is how much of tirzepatide's insulin sensitivity benefit is a direct receptor effect versus a consequence of losing fat. The clamp data suggest a direct component, but dedicated studies isolating the GIP contribution in humans are limited, and published research should be read with that caveat.
The bottom line
Tirzepatide works by activating the GIP and GLP-1 receptors together, which lowers appetite, slows gastric emptying, increases glucose dependent insulin release, suppresses glucagon, and improves how fat tissue and muscle respond to insulin. The GLP-1 half explains most of what people feel day to day, while the GIP half appears to explain why the results exceed those of GLP-1 only medications.
Tirzepatide is a prescription medication with important safety considerations, including a boxed warning regarding thyroid C-cell tumors seen in rodent studies. Anyone considering treatment should discuss their full medical history with a licensed clinician, because the medication's effects on glucose, gastric emptying, and appetite interact with many other conditions and drugs.
Take the next step
Talk with a licensed provider
A 2 minute intake connects you with a licensed provider who reviews your health history and discusses whether treatment is appropriate for you.
$89 first month, then $199/month. Cancel anytime.
Start Your Journey Prescription only if clinically appropriate.